HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Plan B Pioneers OTC “Pharmacy Counter” Approval, Dual-Status Marketing

This article was originally published in The Tan Sheet

Executive Summary

FDA's decision to approve emergency contraceptive Plan B for over-the-counter sale to women age 18 and older cracks open the door on a pharmacy-only, behind-the-counter model for nonprescription drug sales

You may also be interested in...



Gedeon Richter To Market HRA Pharma’s Novel Emergency Contraceptive, ellaOne

HRA expects to file an NDA for ellaOne in the U.S. by end of year.

Von Eschenbach Resigning In January With BTC Debate In His Legacy

FDA Commissioner Andrew von Eschenbach will return to Texas upon resigning his post Jan. 20, leaving a legacy that includes restarting discussions on whether a third class of drugs is needed

Researcher In Plan B Survey Supports Removing Age Restriction

The safety record of emergency contraceptive Plan B supports removing age restrictions on sales of the product, according to Rebekah E. Gee, the lead researcher behind a survey on access to the drug and an advocate for women's access to reproductive medicine

Related Content

Topics

UsernamePublicRestriction

Register

RS125381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel